Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01185288 · ClinicalTrials.gov registry record · Phase 4
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
A Phase 4 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 4
- Development phase
- 309
- Enrollment target
NCT01185288 is a Phase 4 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 309 participants.
The verdict
NCT01185288, a Phase 4 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 309 participants
- Enrollment target
Study Summary
This study will investigate the efficacy of both low and high doses of methotrexate (MTX) in combination with open-label adalimumab (ADA) in patients who have had an inadequate response to high dose of MTX. The study will also evaluate the pharmacokinetics and safety of the two regimens of MTX in combination with ADA in participants with rheumatoid arthritis (RA).
Interventions
- BIOLOGICAL Adalimumab
- DRUG Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 309 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01185288
The ClinicalTrials.gov registry entry for NCT01185288 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 309 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Adalimumab is the first listed.
NCT01185288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01185288 about?
NCT01185288 is a clinical study titled "A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)". This study will investigate the efficacy of both low and high doses of methotrexate (MTX) in combination with open-label adalimumab (ADA) in patients who have had an inadequate response to high dose of MTX. The study will also evaluate the pharmacokinetics and safety of the two regimens of MTX in co...
What is the current status of trial NCT01185288?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 309 participants. The study started on 2010-09. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01185288?
The interventions under investigation include: Adalimumab (BIOLOGICAL), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT01185288?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.